Drug Profile

Recombinant human thrombin - Zejing Pharmaceutical

Latest Information Update: 10 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zejing Pharmaceutical
Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
Mechanism of Action Thrombin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preregistration Unspecified

Most Recent Events

07 Dec 2023 Recombinant human thrombin licensed to Yuanda Life Sciences in China
31 May 2022 NMPA approves marketing authorisation application for Recombinant human thrombin in China, before May 202
30 Apr 2022 Preregistration for Unspecified in China (unspecified route), before April 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com